Progenics Rises as Constipation Drug Shows Benefits in Trial
This article is for subscribers only.
Progenics Pharmaceuticals Inc., the developer of an injected constipation treatment, gained the most in three years after an oral version of the drug helped patients in a late-stage trial.
Progenics rose 31 percent to $8.49 at the close of New York trading, the biggest gain for the Tarrytown, New York-based company since April 2008. Salix Pharmaceuticals Ltd., which licenses the medication, climbed to its highest price in 11 months.